Susquehanna International Group, LLP Gamida Cell Ltd. Put Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 07, 2024	BUY	$0.04 - $0.46 $832 - $9,568	20,800 Added 103.48%	40,900 $1,000
Q4 2023 Feb 14, 2024	SELL	$0.25 - $1.02 $30,250 - $123,420	-121,000 Reduced 85.75%	20,100 $8,000
Q3 2023 Nov 14, 2023	BUY	$0.85 - $1.87 $52,020 - $114,444	61,200 Added 76.6%	141,100 $145,000
Q2 2023 Aug 11, 2023	BUY	$0.73 - $2.37 $31,317 - $101,673	42,900 Added 115.95%	79,900 $154,000
Q1 2023 May 16, 2023	BUY	$0.68 - $1.71 $4,624 - $11,628	6,800 Added 22.52%	37,000 $29,000

Q4 2022 Feb 14, 2023	SELL	$1.15 - $2.1 $18,860 - $34,440	-16,400 Reduced 35.19%	30,200 $38,000
Q3 2022 Nov 14, 2022	SELL	$1.53 - $3.39 $26,010 - $57,630	-17,000 Reduced 26.73%	46,600 $74,000

11.4M

235K

70.5K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.